Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
A 12 Month, Open-Label, Flexible Dosage Extension Study of the Safety and Efficacy of
Armodafinil (CEP-10953) in the Treatment of Patients with Excessive Sleepiness Associated
with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep
Disorder